Multi-agent AI delivers reliable and scalable insights for single-cell omics
Episode
43 min
Read time
2 min
Topics
Productivity, Investing, Fundraising & VC
AI-Generated Summary
Key Takeaways
- ✓Single-cell analytics pipeline structure: Divide single-cell workflows into three distinct phases — primary (raw sequencing to structured gene-cell matrix), secondary (clustering, batch correction via tools like Scanpy or Seurat), and tertiary (biological interpretation and annotation). Pharma now considers the first two phases stable enough for regulatory submissions; the tertiary phase remains the primary bottleneck and efficiency target.
- ✓Cherry-picking risk over hallucination: When deploying LLMs for cell annotation, the greater danger is not fabricated outputs but selective gene focus — an LLM assessing 10 genes while ignoring 7. Guard against this by architecting fan-out parallel analysis across thousands of genes simultaneously, then pruning results back, trading speed for comprehensive coverage measured in minutes rather than weeks.
- ✓Agentic annotation with evidence trails: CytType uses specialized LLM agents that cross-reference marker genes against literature, validate conclusions, and log every rejected hypothesis into structured data models. This produces traceable HTML reports with a chat interface, allowing wet-lab biologists to interrogate annotation reasoning directly without routing every question back through bioinformaticians.
- ✓Annotation resolution determines downstream discovery value: Coarse cell-type labels degrade differential expression analysis, pathway analysis, and target prioritization built on top of them. Resolving subtypes — distinguishing pro-inflammatory from suppressive macrophages, or active from exhausted T cells — directly determines whether a patient qualifies for cell therapy and enables reproducible biomarker validation across cohorts and time points.
- ✓Virtual cell models are 4–5 years from deployment: Foundation models like scGPT apply transformer architectures to single-cell data but currently underperform classical machine learning on benchmarks. Federated pharma infrastructure initiatives, such as Eli Lilly's TuneLab with NVIDIA, are accumulating the large-scale perturbation datasets needed for emergent reasoning capabilities, but practical deployment systems remain at least four to five years away.
What It Covers
Parashar Dhapola, CEO of NIGEN Analytics, explains how multi-agent AI systems address the core bottleneck in single-cell omics: cell type annotation. He covers where AI genuinely delivers in biopharma, why cherry-picking poses greater risk than hallucination, and how CytType compresses weeks of iterative analysis into minutes.
Key Questions Answered
- •Single-cell analytics pipeline structure: Divide single-cell workflows into three distinct phases — primary (raw sequencing to structured gene-cell matrix), secondary (clustering, batch correction via tools like Scanpy or Seurat), and tertiary (biological interpretation and annotation). Pharma now considers the first two phases stable enough for regulatory submissions; the tertiary phase remains the primary bottleneck and efficiency target.
- •Cherry-picking risk over hallucination: When deploying LLMs for cell annotation, the greater danger is not fabricated outputs but selective gene focus — an LLM assessing 10 genes while ignoring 7. Guard against this by architecting fan-out parallel analysis across thousands of genes simultaneously, then pruning results back, trading speed for comprehensive coverage measured in minutes rather than weeks.
- •Agentic annotation with evidence trails: CytType uses specialized LLM agents that cross-reference marker genes against literature, validate conclusions, and log every rejected hypothesis into structured data models. This produces traceable HTML reports with a chat interface, allowing wet-lab biologists to interrogate annotation reasoning directly without routing every question back through bioinformaticians.
- •Annotation resolution determines downstream discovery value: Coarse cell-type labels degrade differential expression analysis, pathway analysis, and target prioritization built on top of them. Resolving subtypes — distinguishing pro-inflammatory from suppressive macrophages, or active from exhausted T cells — directly determines whether a patient qualifies for cell therapy and enables reproducible biomarker validation across cohorts and time points.
- •Virtual cell models are 4–5 years from deployment: Foundation models like scGPT apply transformer architectures to single-cell data but currently underperform classical machine learning on benchmarks. Federated pharma infrastructure initiatives, such as Eli Lilly's TuneLab with NVIDIA, are accumulating the large-scale perturbation datasets needed for emergent reasoning capabilities, but practical deployment systems remain at least four to five years away.
Notable Moment
Dhapola reframes the standard AI risk conversation by arguing that preventing an LLM from lying is the easier engineering problem — the harder, less-discussed challenge is forcing it to examine all available data rather than fixating on a convenient subset, a failure mode that mirrors how human experts also reason.
Episode Transcript
Hello, and welcome to Beyond Biotech, the weekly podcast from Labiatek. I'm Dylan Kasein, and this is episode 192 for the podcast. Today, we're exploring the transformative power of AI in biopharma, separating hype from reality and zooming in on the complexities of single cell omics data. Our guest is Parashar Dipola, cofounder and CEO of NIGAN Analytics, a Lund based start up spun out from Sweden's single cell genomics ecosystem. With a PhD in computational genomics from Lund, Parashore has pioneered efficient algorithms for analyzing millions of cells, turning raw data into actionable insights for drug discovery. Join us as we discuss where AI truly delivers in biopharma, the persistent gaps in exploratory data analytics, and the critical bottlenecks in single cell annotation. In a world of bounding in AI hype, Parasha helps us cut through the noise and points out paths to data driven success. Parasha, welcome to Beyond Biotech. Thanks, London, and thanks for having me. Let's start here. Now your background is in computational genomics. You did your PhD at Lund University. What were you working on? What was the problem that eventually led you to start the company? Great. I mean, there were two aspects to my to my PhD, and the first one was to hunt for, cancer stem cells in, in leukemia. And, that's where what we were doing is, using single cell technologies to really look for, needle in a haystack sort of a situation. And, and the other aspect of my PhD was, was to develop a scalable infrastructure for analyzing all this data. And that's where I was really obsessed with with scalability, building new algorithms that will allow us to analyze millions of cells, with very little sort of resources available. And, and that's where we had a breakthrough in a way that, or one can call it a light bulb moment where we saw that that now with some of the algorithms that we have developed, we could really scale out to millions of sales without requiring a massive high performance computing system, but essentially be able to do that on your laptop if if needed. And one could say that that was also what kind of seeded the idea that, you know, we potentially now could put all this compute on the cloud, which is very resource efficient. So we can also make it accessible to a lot of idea a lot of other people. And and that's where the kind of the idea of Nijen also, became, you know, something of a seed to to start on. Nijen, like you say, it spun out of this work that you were doing at LAN. That's really one of the most productive areas in in Sweden for new research. Did being embedded in that environment shape what you decided to build in the end? Absolutely. Absolutely. We were very fortunate to be, part of, the Lunds, single cell ecosystem, so to say. So my cofounder, Jeroen Carlson, he …
Get the full transcript (8,012 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 40-minute episode.
Get Beyond Biotech summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from Beyond Biotech
Beyond biology: Nanobiotix's physics-first approach to cancer
Aug 21 · 31 min
Eye on AI
Why the Future of AI Isn't Just Bigger Models. It's Models That Evolve | Risto Miikkulainen of Cognizant
Jun 2
More from Beyond Biotech
How Cancer Research Horizons is building the future of childhood cancer medicines
Aug 14 · 43 min
Software Engineering Daily
Vespa AI and Surpassing the Limits of Vector Search
May 12
Books, tools, and gear mentioned in this episode
SignalCast may earn commission on purchases via these links.
Tools
“Foundation models like scGPT apply transformer architectures to single-cell data but currently underperform classical machine learning on benchmarks.”
by Eli Lilly
“Federated pharma infrastructure initiatives, such as Eli Lilly's TuneLab with NVIDIA, are accumulating the large-scale perturbation datasets needed for emergent reasoning capabilities”
“clustering, batch correction via tools like Scanpy or Seurat”
“how CytType compresses weeks of iterative analysis into minutes”
“clustering, batch correction via tools like Scanpy or Seurat”
More from Beyond Biotech
We summarize every new episode. Want them in your inbox?
Beyond biology: Nanobiotix's physics-first approach to cancer
How Cancer Research Horizons is building the future of childhood cancer medicines
Why Western pharma is sleeping on China's circular RNA revolution
Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson's
This nonprofit is building the ecosystem to cure epidermolysis bullosa
Similar Episodes
Related episodes from other podcasts
Eye on AI
Jun 2
Why the Future of AI Isn't Just Bigger Models. It's Models That Evolve | Risto Miikkulainen of Cognizant
Software Engineering Daily
May 12
Vespa AI and Surpassing the Limits of Vector Search
Software Engineering Daily
May 5
SmartBear and Multi-Agent QA
The TWIML AI Podcast
Apr 16
How Capital One Delivers Multi-Agent Systems with Rashmi Shetty - #765
Moonshots with Peter Diamandis
Dec 23
Why We Need New AI Benchmarks, Which Industries Survive AI, and Recursive Learning Timelines | #218
Explore Related Topics
This podcast is featured in Best Biotech Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Investing & Markets Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into Beyond Biotech.
Every Monday, we deliver AI summaries of the latest episodes from Beyond Biotech and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime